Category Archives: Genetics

DNA Genetics Announces Agreement With Green Peak To Make The Most Of Michigan Adult-Use Cannabis Market – Yahoo Finance

OG DNA Genetics recently disclosed a licensing agreement in conjunction with Green Peak Innovations, a medical cannabis producer and distributor in the Michigan market.

This arrangement will concede Green Peak Innovations consent to the DNA brand and access to their genetics portfolio for use at the companys cannabis cultivation and processing plant in Harvest Park, Michigan. Additionally to growing DNA genetics, Green Peak has entered the retail sector, with several locations around the state.

The recent permit of adult-use cannabis police in Michigan will enable Green Peak to supply recreational and medical users high-quality strains.

Want to hear exclusive updates on the adult-use licensing process? Check out the next meetup with MRA Executive Director, Andrew Brisbo on Dec. 18 at the Benzinga Headquarters! Get your tickets here before they sell out!

"By partnering with Green Peak Innovations, we position ourselves to expand into the rapidly developing Michigan cannabis market alongside a proven and trusted cannabis producer and distributor," said Charles Phillips, CEO of DNA Genetics.

Jeff Radway, CEO of Green Peak Innovations said, "We appreciate what DNA has accomplished for the cannabis industry and are excited to partner with them. We believe that by incorporating DNAs library of best-in-class cultivars and award-winning genetics into our facility, we can further enhance our ability to deliver the highest-quality products to Michigan and eventually the entire United States."

0

See more from Benzinga

2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read more here:
DNA Genetics Announces Agreement With Green Peak To Make The Most Of Michigan Adult-Use Cannabis Market - Yahoo Finance

DNA Genetics Announces Strategic Partnership With Green Peak Innovations Signaling Their Entry Into the Michigan Medical and Adult Use Cannabis…

LOS ANGELES, Dec. 10, 2019 (GLOBE NEWSWIRE) -- OG DNA Genetics (DNA or the Company), a globally recognized leading cannabis brand, today announced a licensing agreement (the Agreement) with Green Peak Innovations (Green Peak or GPI), the leading producer and distributor of medical and adult-use cannabis in the Michigan market.

This Agreement will grant Green Peak Innovations license to the DNA brand and access to their proprietary library of award-winning genetics for use at the companys state-of-the-art, 73,000-square-foot cannabis cultivation and processing facility in Harvest Park, Michigan. In addition to cultivating DNA genetics, Green Peak has expanded its vertically integrated business to include premium retail stores, with locations currently open around the state. The recent passage of adult-use cannabis laws in Michigan will allow Green Peak to offer recreational and medical consumers the highest quality strains in the market.

By partnering with Green Peak Innovations, we position ourselves to expand into the rapidly developing Michigan cannabis market alongside a proven and trusted cannabis producer and distributor, said Charles Phillips, CEO of DNA Genetics. Green Peak Innovations commitment to best practices, the highest-quality products and emphasis on integrity perfectly align with what we look for in potential licensing partners.

For more than 15 years, genetics developed by DNA have won more than 200 awards in all categories at the most prestigious cannabis events around the world, making DNA the global standard in breeding and growing truly best-in-class strains. These awards include the High Times Top 10 Strain of the Year, which was inducted into The High Times seedbank hall of fame in 2009, the High Times 100 list of the most influential people in the industry and theHigh Times Trailer BlazersAward, for contributions made towards uniting the fields ofentrepreneurship, politics and medicine.

We appreciate what DNA has accomplished for the cannabis industry and are excited to partner with them. We believe that by incorporating DNAs library of best-in-class cultivars and award-winning genetics into our facility, we can further enhance our ability to deliver the highest-quality products to Michigan and eventually the entire United States, said Jeff Radway, CEO of Green Peak Innovations.

Consumers in Michigan can expect to see DNA genetics available in Green Peaks Skymint-branded retail stores and via provisioning centers around the state under the companys North Cannabis wholesale brand as soon as Summer 2020.

About OG DNA Genetics Inc.

DNA was rooted in Los Angeles and founded in Amsterdam in 2004 by Don Morris and Aaron Yarkoni. Over the last decade, the Company has built and curated a seasoned genetic library and developed proven standard operating procedures for genetic selection, breeding, and cultivation. In a world that is increasingly opening up to commercial cannabis activity, DNA is positioned to become the first, truly geographically-diversified company with multiple partnerships with top-licensed producers and brands that have built their companies and global presence utilizing the Powered by DNA model. For more information, please visit http://www.dnagenetics.com.

For further information, please contact Rezwan Khan, Vice President, Global Corporate Development at rezwan@dnagenetics.com

About Green Peak Innovations

Green Peak Innovations is Michigans leading vertically integrated cannabis company and the states largest medical and recreational license holder. With two state-of-the-art indoor grow facilities, the company cultivates, processes, markets and distributes a full range of branded cannabis products, including Skymint, North Cannabis, Jolly, Evoxe Laboratories, Agata and St. Jade. GPI products can be found at the companys Skymint provisioning centers and via the North brand, retailers around Michigan through a robust wholesale network.

As purveyors of premium-crafted cannabis, weve developed a portfolio of the finest cannabis brands available for daily wellness, healing or just getting high on life. GPI inspires individuals to UNLOCK their mental, physical and spiritual potential through cannabis.

For more information, visit http://www.greenpeakinnovations.com.

Media Contact: Jordan Walker, jwalker@identitypr.com.

See the original post:
DNA Genetics Announces Strategic Partnership With Green Peak Innovations Signaling Their Entry Into the Michigan Medical and Adult Use Cannabis...

Does the ‘genetics revolution’ unsettle you? Here is a guide, and reasons to be hopeful – Genetic Literacy Project

Its that time of year again an avalanche of ads urging us to drool into tubes so companies can spit back verdicts on our pasts, presents, and futures. Judging from my emails, those unceasing ads have inspired many questions about genetics in general.

Among the emails that pinged in recently:

So I started a list of my e-mails, with apologies to Hillary, and extracted three recurring themes: transgender identity, when a human life begins, and by far the largest group: interpreting DNA test results, either consumer or clinical.

What do you think about a new studythat found 20 genetic markers of transgender identity? asked a reporter from The Times of London In March 2018. Id suggested just such a study a year earlier, which hed found here.

Impressed with the study, I agreed to comment. But the reporter forgot to distinguish me from the researcher, and so throughout Europe, I was suddenly an expert on transgender genes. And that inspired some telling emails.

The first, from a trans woman born in 1948, shared her 70-page story:

As far back as I can remember I thought nothing of going into my mothers closet, pulling down her nightgowns, and putting them on. They were soft, they smelled of her, and they felt so perfect. This was me. Everything feminine fascinated me. Anything male repelled me. I wanted to emerge myself in the female world. But no matter what I did, I just couldnt look like Mommy.

Another transgender woman wrote:

I would love to have that degree of certainty that a genetic study would show. Parents would be able to perhaps work with their children instead of ignoring it either intentionally or out of ignorance.

A recent email from 58-year-old Edith brought up nature v nurture:

Two of my nine nieces and nephews are transitioning. My family has an overall fluid concept of gender identity, which we discussed with each other before either child made it known they were trans. I find myself wondering if this is true in other families.

Me too.

I repost 17 timepoints whenever womens reproductive rights are threatened, or I read or hear a comment that indicates ignorance of biology. The idea of the list came to me when considering that an embryos genome turns on at day 5, but it cant possibly exist at that point outside of a womans body.

One woman asked about fetal rights. Her ex had given her an herbal abortion tea without her knowledge when she was pregnant. Her baby so far is healthy, but she wants a court to recognize the tea-poisoning as child abuse. At what point in utero does a fetus have rights? It seems to vary state to state, she wrote.

Celia Collias, a statistics major at the University of North Carolina, offered a compelling perspective: distinguishing two types of viability. Natural ability to be physiologically independent for a human fetus is around 24 weeks. Technologically assisted viability for a human fetus is 21 weeks.

If we dont use natural viability as the cut off for reproductive rights, Ms. Collias argues, then those rights will erode as technology sets back the age of assisted viability:

Technologically assisted viability is not free. If we allow that to be the benchmark, its going to cost society a lot to care for all those fetuses where would that money come from?

Good question.

Is he really my brother? asked the woman who sent me scanned columns of genetic markers. I circled 16 of 38 that they share and sent it back: Yes.

I dont have mutations in BRCA1 or 2, so Im ok, right? I do have a mutation in ATM (or p53 or CHEK2 or PTEN or RAD51 or a few dozenothers). Inherited mutations for cancer risk go beyond the most common ones in the BRCA pair, and altogether they account for only 5 percent of cases. Yes, shes at high risk.

BRCA brings up the limited variant problem. Consumer DNA tests, for cancer or single-gene diseases, are likely to check for only the most common variants, such as a handful of mutations in the CFTR gene behind cystic fibrosis, which has more than 1,700. These health reports may provide a false sense of reassurance and should not be used for making any health decisions without confirmation testing, said Edward Esplin, MD, of Invitae, a clinical testing company, at the American Society of Human Genetics conference in October, catalyzing a flood of headlines.

I had a prenatal screen for 125 genes and one is a variant of uncertain significance. What the heck is a VUS? Do I have a mutation or not?

A VUS is a gene variant that isnt common, but hasnt shown up in someone with a disease and reported in the medical literature. Yet. I explain here.

My ethnicity estimate changed overnight. Huh? When an ancestry company adds a new group to its database of reference populations, the sections of those pie charts can shift, or a new one appear.

Im 20 weeks pregnant. The fetus has a microduplication of chromosome 18. Is that a problem? The healthy dad-to-be also had the tiny extra bit of DNA. So, no.

I just found out that I have an extra Y chromosome. Ive had severe acne since my early teens, and today Im 62 and weigh 295 pounds. Im a biker, football player, and served time for selling pot. Did my extra chromosome get me arrested?

Probably not. Being in the wrong place at the wrong time, before decriminalization, was more likely at fault.

Because most of my email brings up medical matters, heres a short guide to getting help in making sense of DNA test results related to health. (For interpreting ancestry findings, the International Society of Genetic Genealogy is an excellent resource.)

Its important to distinguish consumer DNA tests, which anyone can take by purchasing a kit and spitting or swizzling a cheekbrush, from clinical DNA tests, which a health care provider orders and the FDAs Clinical Laboratory Improvement Amendments (CLIA) regulate.

Like mushrooms materializing after a warm rain, articles, websites, books and companies are springing up to help consumers navigate test-taking and interpretation.

Finding an expert specifically trained at the graduate level in genetics a genetic counselor, PhD geneticist, or MD with genetics/genomics training is challenging because their priorities are in clinical testing, not the entertainment/education space that the consumer companies so ceaselessly promote. Other scientists may be helpful molecular biologists, biochemists but genetics as a discipline transcends DNA, including developmental, transmission, and population and evolutionary genetics too. Ancestry testing in particular melds these levels of genetics.

Assuming a sit-down with an expert to intrepret consumer DNA data isnt happening easily, here are some places to turn.

A longstanding helpful website is Genetics Home Reference, from the NIH.

A newer resource is this report from ConsumersAdvocate.org. Their researchers recently sent DNA anonymously to 9 leading consumer DNA testing companies, interpreted the data, and then wrote a detailed, clear analysis that compares the services, privacy/security measures, online resources, and cost of tests.

Consumer DNA testing is a fast-growing industry with over 26 million users worldwide. That number is expected to grow to 100 million by 2021, Sam Klau, Community Outreach at the organization, told me.

An excellent new book is DNA Nation: How the Internet of Genes is Changing Your Life, by PhD molecular biologist Sergio Pistoi. And my human genetics textbook will be out in a new edition in September. Ive added a chapter called The Genetics of Identity, inspired by having my past rewritten recently thanks to ancestry testing.

The testing company websites, like that of 23andme, provide clear and well-written info on interpreting test results. But without any prior knowledge of genetics, misinterpretation and misplaced angst can arise.

Does the average person know the difference in significance between revealing a pattern of genome-wide single-base variations (SNPs) associated with elevated risk of a trait or illness, and detecting a well-studied mutation in a single gene?

The raw data dump from consumer DNA testing can be overwhelming, and to paraphrase Elizabeth Warren: Theres a company for that. A consumer can pay to avoid bushwhacking through dense SNP forests.

Strategene, for example, is a genetic reporting tool that uses 23andMe data to identify SNPs in a few dozen well-studied, health-related genes, and not every SNP under the sun. The $45 is a sound investment; it would take hours to sort through Google Scholar to DIY. But the client needs to know about the limited variant issue of checking only for common SNPs.

(I was briefly fooled into confusing the company with 1980s biotech giant Stratagene, but its off by one letter and one capitalization. The only person named on the company website is a naturopath referred to many times as Dr., which wouldnt necessarily denote a genetics expert.)

Im curious to see how soon the medical profession catches up. Right now, genetic counselors in the US number only about 5,000. But professional organizations are stepping in. The American College of Medical Genetics and Genomics, for example, offers online continuing medical education, ACMG Genetics 101 for Healthcare Providers.

But doctors Ive encountered recently still go deer-in-the-headlights when I ask a genetics question, just to be obnoxious. And so a company like ActXmakes sense in helping medical professionals keep pace with the growing tide of patients coming in waving consumer DNA test results. The company helps physicians and patients apply 23andMe raw data to select drugs, order clinical tests to help diagnose specific conditions, and to confirm carrier status for single-gene diseases.

When I started my career as a Drosophila geneticist, mutating flies to grow legs out of their heads, I never imagined at-home DNA testing. When I started my career as a science writer and textbook author, I still couldnt have predicted at-home DNA testing. Now that its here, Im thrilled that DNA science has become so much more tangible and practical. Yet we must use the information in our strings of A, C, T, and G wisely.

Ricki Lewis is the GLPs senior contributing writer focusing on gene therapy and gene editing. She has a PhD in genetics and is a genetic counselor, science writer and author of The Forever Fix: Gene Therapy and the Boy Who Saved It, the only popular book about gene therapy. BIO. Follow her at her website or Twitter @rickilewis

Read the original:
Does the 'genetics revolution' unsettle you? Here is a guide, and reasons to be hopeful - Genetic Literacy Project

New Data from Ambry Genetics Showed Concurrent RNA and DNA Testing Identified More Patients with Hereditary Breast Cancer than DNA Testing Alone -…

ALISO VIEJO, Calif., Dec. 10, 2019 /PRNewswire/ --Researchers atAmbry Genetics(Ambry), a leading clinical genetic testing lab, will announce new data showing that conducting RNA and DNA tests for hereditary cancer risk at the same time identifies more patients with mutations that increase cancer risk than DNA testing alone. To be presented at the San Antonio Breast Cancer Symposium (SABCS) this week, the data come from a study of 746 patients with breast cancer that received +RNAinsight, paired RNA and DNA genetic testing for hereditary cancer risk.

Standard DNA testing for hereditary cancer risk excludes large portions of DNA, thereby missing some mutations. In addition, DNA testing can produce inconclusive results and fail to determine that an error in our DNA increases cancer risk. These limitations impact patients and their families because doctors may not have the information needed to recommend appropriate preventive, early detection, or therapeutic steps. Additionally, relatives may not be referred for genetic testing and obtain the care they would otherwise have gotten if they had learned they had mutations.

Adding RNA to DNA testing overcomes these limitations for a substantial number of patients as it provides considerably more evidence than DNA testing alone about whether our DNA has mutations.

The data showed that adding RNA genetic testing to DNA testing increased the diagnostic yield the number of people found to have a mutation that increases cancer risk across 16 hereditary breast and/or ovarian cancer genes. As a result of +RNAinsight, five breast cancer patients were identified to have mutations in clinically-actionable genes that would have otherwise been missed completely or the patient would have received inconclusive results if they had received DNA testing only. These findings included three women with mutations in BRCA1/2, one woman with a mutation in ATM, and one woman with a mutation in PMS2. Additionally, paired RNA and DNA genetic testing decreased the number of inconclusive results, giving patients more definitive answers about whether their breast cancers were hereditary. Additional results will be presented on an expanded breast cancer cohort at the meeting on Saturday, December 14th.

"These data further prove that paired RNA and DNA genetic testing for hereditary cancer should be the industry standard," said Holly LaDuca, MS, CGC, senior manager of Ambry's clinical affairs research. "Our research has consistently shown that +RNAinsight provides clinicians with more accurate results, better informing patient care."

Researchers from Ambry will also present at SABCS new data from a pre-and post-test clinician survey that assessed how genetic testing for hereditary cancer impacted medical management, such as screening recommendations. The survey found that positive genetic testing results frequently lead to changes in management recommendations in both high risk (e.g. BRCA1) and moderate risk (e.g. ATM) genes. Changes to mammogram, breast MRI, and/or preventive surgery options were reported in 77.3% of positive individuals. Moreover, medical management changes largely adhered to published guidelines, indicating that cliniciansare applying recommendations appropriately based on test results.

"With this survey data, clinicians are showing us that they truly do use genetic testing results to implement personalized recommendations, which can be life-saving for a patient," said Carrie Horton, MS, CGC, senior researcher in Ambry's clinical affairs team. "These data provide further evidence that genetic testing is essential to comprehensive cancer care. Continued study in this area will aid clinicians, laboratories, health plans, and ultimately patients."

Below are summaries of each of the four studies that Ambry will present at SABCS 2019.

Friday, December 13, 5:00- 7:00 PM CST

P5-07-06,Black M, et. al., Performance of Polygenic Risk Score Combined with Clinical Assessment for Breast Cancer Risk

Saturday, December 14, 7:00 9:00 AM CST

P6-08-35,Horton C, et. al., Impact of Multigene Panel Testing on Medical Management: Preliminary Results of a Pre- and Post- Test Clinician Survey

P6-08-08,LaDuca H, et. al., Concurrent DNA and RNA Genetic Testing Identifies More Patients with Hereditary Breast Cancer than DNA Testing Alone

P6-08-04,Yadav S, et. al., Germline Mutations in Cancer Predisposition Genes in Patients with Invasive Lobular Carcinoma of the Breast

ABOUT AMBRY GENETICS

Ambry Genetics, as part of Konica Minolta Precision Medicine, excels at translating scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. Our unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means we are first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions. We care about what happens to real people, their families, and the people they love, and remain dedicated to providing them and their clinicians with deeper knowledge and fresh insights, so together they can make informed, potentially life-altering healthcare decisions. For more information, please visitambrygen.com.

For more information on risk factors for hereditary cancer, please visit cancer.gov's fact sheet on hereditary cancer and genetic testing.

ABOUT +RNAINSIGHT

+RNAinsight, paired with Ambry Genetics' hereditary cancer DNA tests, uses next-generation sequencing to concurrently analyze a patient's DNA and RNA, another layer of genetic information. +RNAinsight identifies more patients who have mutations that increase their cancer risks than through standard DNA-only testing by overcoming limitations of DNA testing. +RNAinsight enables more accurate identification of patients with increased genetic risks for cancer, finds actionable results that may otherwise be missed, and decreases the frequency of inconclusive results. +RNAinsight is now available through doctors and genetic counselors around the country. For more information on +RNAinsight, please go toambrygen.com/RNAinsight.

Press Contact:Liz Squirepress@ambrygen.com (202) 617-4662

View original content:http://www.prnewswire.com/news-releases/new-data-from-ambry-genetics-showed-concurrent-rna-and-dna-testing-identified-more-patients-with-hereditary-breast-cancer-than-dna-testing-alone-300972165.html

SOURCE Ambry Genetics

See the original post here:
New Data from Ambry Genetics Showed Concurrent RNA and DNA Testing Identified More Patients with Hereditary Breast Cancer than DNA Testing Alone -...

Halo Partners with DNA Genetics to Launch Leading World-Renowned Genetics in Oregon – Business Wire

TORONTO--(BUSINESS WIRE)--Halo Labs Inc. (Halo or the Company) (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that it has signed a strategic partnership agreement with OG DNA Genetics Inc. (DNA Genetics), one of the most awarded names in cannabis, to exclusively develop its genetics in Oregon through breeding, growing, phenotyping and processing. The initial term of the partnership agreement is five years with successive five-year renewals.

Partnership Highlights

- DNA Genetics has garnered over 180 awards in the cannabis industry including High Times top 10 strain of the year, seedbank Hall of Fame, and Trail Blazers award

- Their strains and derivative products command a premium in the market and are highly demanded by cannabis consumers

- 5-year exclusive partnership will expand on Halos already prominent genetics library to establish a new standard of cannabis in Oregon

- Partnership aligns with the 1 acre increase in the grow operation in East Evans Creek

- Halo will be only grower and manufacturer of DNA Genetics brand products in Oregon

Founded in Amsterdam in 2004, DNA Genetics is a leading influencer in the global cannabis industry, developing high-quality seeds using a professional, responsible and technical approach. DNA Genetics created some of the most well-known products by combining high quality genetics and expert growing practices. With a win in every single category of the HIGH TIMES Cannabis Cup, many of the top seed companies in the industry use DNA within their breeding programs.

DNA will take that expertise and award-winning track record to produce strains that will be exclusive to Halo in the state of Oregon. The exclusivity requires that companies in Oregon that seek access to the DNA strains must license them from Halo.

Andreas Met, Co-founder and COO of Halo commented, We have seen that consumers demand quality and the top brands in our industry. DNA Genetics provides just that. We expect that demand for our products across the board will benefit from the co-branding opportunities this alliance presents. Mr. Met went on to state, Our recent cultivation expansion provides us an opportunity to capitalize on the DNA Genetics partnership. We will refine genetics of the cannabis that Halo currently produces while introducing new DNA strains into circulation.

We are very excited to partner with Halo Labs. They have an impressive footprint with first-class established product categories, said Charles Phillips, CEO of DNA Genetics. This is a multiplier for two fast-growing cannabis companies with additional partnership opportunities on the horizon. With both companies actively expanding business activities and global footprint we expect this to be a very successful and mutually beneficial partnership.

Commenting on the full potential Kiran Sidhu, Co-founder and CEO of Halo said, We are excited to partner with DNA Genetics to build upon our strains in Oregon. DNA Genetics is renowned through the cannabis industry as a top breeder. Having exclusive rights to their genetic developments in Oregon reaffirms our leading position in this market and will help the Oregon market reach new heights. He added, We hope this is the first of many markets in which Halo and DNA will collaborate.

About HaloHalo is a global cannabis extraction company that develops and manufactures quality cannabis oils and concentrates, which are the fastest growing segments in the cannabis industry. Halo is a global leader in cannabis oil and concentrates, having produced over 4.5 million grams of oils and concentrates since inception. The Company has expertise across all major cannabis manufacturing processes, leveraging a variety of proprietary processes and products. The forward-thinking company is led by a strong management team with deep industry knowledge and blue-chip experience. The Company is currently operating in California and Oregon, as well as in Nevada with our partner Just Quality, LLC, and in Lesotho with the 205-hectare Bophelo cultivation zone.

With a consumer-centric focus, Halo will continue to market innovative, branded, and private label products across multiple product categories. Halo recently acquired Dispensary Track platform which will alleviate customer flow constraints experienced by dispensaries and enable direct consumer interaction.

For further information regarding Halo, see Halos disclosure documents on SEDAR at http://www.sedar.com.

About OG DNA Genetics Inc.DNA was rooted in Los Angeles and founded in Amsterdam in 2004 by Don Morris and Aaron Yarkoni. Over the last decade, the Company has built and curated a seasoned genetic library and developed proven standard operating procedures for genetic selection, breeding, and cultivation. In a world that is increasingly opening up to commercial cannabis activity, DNA is positioned to become the first, truly geographically diversified company with multiple partnerships with top-licensed producers and brands that have built their companies and global presence utilizing the Powered by DNA model. For more information, please visit http://www.dnagenetics.com.

Cautionary Note Regarding Forward-Looking Information and StatementsThis press release contains certain forward-looking information within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Halos beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Halos control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as plans, expects or does not expect, is expected, budget, scheduled, estimates, forecasts, intends, anticipates or does not anticipate, or believes, or variations of such words and phrases or may contain statements that certain actions, events or results may, could, would, might or will be taken, will continue, will occur or will be achieved. The forward-looking information and forward-looking statements contained herein may include, but is not limited to, statements regarding the partnership with DNA Genetics and the development and distribution of new strains of cannabis in Oregon and elsewhere.

By identifying such information and statements in this manner, Halo is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Halo has made certain assumptions. Although Halo believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Halo does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to Halo or persons acting on its behalf is expressly qualified in its entirety by this notice.

See the original post:
Halo Partners with DNA Genetics to Launch Leading World-Renowned Genetics in Oregon - Business Wire

Caris Life Sciences, Ambry Genetics Team on New Hereditary Cancer Panel – Clinical OMICs News

Caris Life Sciences has announced it will begin offering Ambry Genetics 67- gene CancerNext Expanded panel to evaluate hereditary risks for cancer. That test will now be available combined with Caris somatic (tumor) tests that analyze a cancers detailed molecular makeup. In a release, Caris says this will be: The most comprehensive, clinically relevant molecular and genetic offering on the market today to guide treatment and management of cancer. The combined Caris and Ambry testing is already available nationwide.

We are committed to providing clinicians with high-quality information they can use to inform treatment decisions, said David D. Halbert, Caris Life Sciences Chairman, CEO and founder. By partnering with Ambry Genetics to better inform patient care, we are able to provide clinicians a greater ability to learn about a cancers molecular composition.

According to the National Cancer Institute, about 10% of cancers are hereditary. Inherited cancers often occur at a relativelyearly age and involve pathogenic variants in one or more genes. The most common hereditary cancer syndromes in women include hereditary breast and ovarian cancer syndrome, Lynch syndrome, LiFraumeni syndrome, Cowden syndrome, PeutzJeghers syndrome, and hereditary diffuse gastric cancer. A hereditary cancer risk assessment identifies patients and families who may be at increased risk of developing certain types of cancer.

Caris currently offers clinicians Caris Molecular Intelligence, a proprietary, comprehensive tumor profiling approach that assesses DNA, RNA, and proteins that are unique to an individuals cancer, among other products. The Molecular Intelligence test reveals a molecular blueprint aimed to guide more precise and individualized treatment decisions.

Through the partnership, Caris will now also offer Ambrys CancerNext-Expandedhereditary cancer panel, which analyzes 67 genes associated with an increased hereditary risk of cancer, including brain, breast, colon, ovarian, pancreatic, prostate, renal, uterine, and many other cancers. This test identifies inherited risks for cancer in order for clinicians to accurately diagnose, treat, and manage cancer risks for each patients needs.

To best diagnose and treat cancer, clinicians must understand whether patients have mutations in genes associated with an increased risk for hereditary cancer, said Aaron Elliott, Chief Executive Officer of Ambry. Caris molecular tests combined with Ambrys germline genetic testing, give clinicians the most comprehensive, clinically relevant molecular profile on the market to guide treatment and management.

Being able to simultaneously conduct comprehensive tumor genomic testing and multi-gene germline sequencing is invaluable, especially for sick patients at the beginning of their cancer journey, said Michael J. Hall, M.D., and chair, Department of Clinical Genetics at Fox Chase Cancer Center. This is information I can immediately begin using for my patients to more accurately diagnose them and to better individualize their treatments.

In further news from Caris, the National Comprehensive Cancer Network (NCCN) updated their treatment guidelines for Non-Small Cell Lung Cancer (NSCLC), which stress the importance ofRNA profilingand noteDNA-based next-generation sequencing may under-detectNTRK1andNTRK3fusions.Caris offers a suite of molecular profiling offerings, including whole transcriptome sequencing with MI Transcriptome which they say provides themost comprehensive and unique RNA analysis available and covers all 22,000 genes.

Visit link:
Caris Life Sciences, Ambry Genetics Team on New Hereditary Cancer Panel - Clinical OMICs News

Extinction of farm animals threatens food security and genetic diversity – ABC News

Australian agriculture is rapidly breeding out diversity within farmed animals, genetics which could one day be the key to stopping diseases and adapting to changing environments.

The University of Western Australia's Catie Gressier said while extinction and biodiversity were issues often associated with native species, heritage and rare breeds of agricultural animals were also under threat, and many had already been lost.

"It's really quite alarming," she said.

"Globally, since the early '90s, we've been losing a breed a month it's a really massive issue.

"With the industrialisation of agriculture, there's been a really strong focus on profitability and there's been a real shift towards a small number of productive hybrids that now dominate the industry almost totally worldwide."

Wessex Saddleback pigs are 'at risk' of extinction in Australia.

(Supplied: James Bennett)

Wessex Saddleback pigs are 'at risk' of extinction in Australia.

Dr Gressier said most breeds had been lost over the past 30 years with market forces dominating what breeds were farmed for meat.

And she said that could be to the peril of agriculture's long-term sustainability.

"Having a biodiverse environment is so critical in order to have a responsiveness and an adaptability to unforeseen changes occurring climatically [and] economically, in terms of consumer preferences, and also in terms of profitability," she said.

Dr Gressier pointed to the current threat of African Swine Fever on the pig industry as a global disease where a range of genetics within existing breeds could be examined for naturally occurring tolerance or resistance.

British White cattle is known for its high eating quality but it is listed as "at risk" by the Rare Breeds Trust of Australia.

(ABC Central Victoria: Larissa Romensky)

British White cattle is known for its high eating quality but it is listed as "at risk" by the Rare Breeds Trust of Australia.

ABC Central Victoria: Larissa Romensky

"Different genetic pools have different capabilities to demonstrate resistance to various diseases," she said.

"We need to have that agility for these new risks.

"In terms of improving stock, a diversity of genetics is really valuable but [so is] mitigating against some of the risks around disease and climate changes that are occurring."

Poultry breeders say it is becoming very difficult to get new genetics for some types of ducks and chickens.

(Contributed: Pip Rumble)

Poultry breeders say it is becoming very difficult to get new genetics for some types of ducks and chickens.

Dr Gressier said Australia had no cryo-conservation facilities to collect and store sperm and embryos and laws for some species, such as pigs, did not permit the importation of genetic material.

"The whole conservation effort is in the hands of individual farmers, volunteer organisations, and rare breed societies such as the Rare Breeds Trust of Australia," she said.

She urged consumers to buy meat from rare breed animals in order to support continued commercial production.

"For example, pork that's coming from Hampshires or Tamworths or Wessex Saddlebacks [pig breeds] that are in a really endangered states," she said.

"If you can support farmers that are growing these breeds that's a really positive step.

"To preserve these animals in our economic situation, it really is about finding how they can have some sort of economic viability."

In the West Australian wheatbelt, Linton and Kerry Batt have run a commercial herd of Berkshire pigs for the past 10 years.

Berkshires produce fewer pigs per litter and are slower to grow in comparison to the Landrace or Large White breeds which dominate commercial piggeries.

Mr Batt said he marketed his Berkshire pork as being the wagyu of the pork sector.

Linton Batt supplies a boutique market with his Berkshire pork, which he says competes on flavour.

(Supplied: Linton Batt)

Linton Batt supplies a boutique market with his Berkshire pork, which he says competes on flavour.

"Our production is aimed at a very small niche; it's a domestic market for super premium pork," he said.

"We've done the numbers, and we know that we need a price premium for our production.

"There is only a small market of people who will pay that price but for us, we're small enough to fill that gap, along with some other excellent Berkshire breeders, and it's worth doing."

Mr Batt said in order for his operation, and his pigs' genetics to survive, he is careful to keep the business viable but is concerned about the agricultural sector losing genetics.

"It should be a concern for everybody; we're seeing gene pools shrink and the loss of diversity," he said.

"We're always looking at the numbers to make sure they are viable and that the business stands on its own merit."

Tina the Wessex saddleback pig. Her breed is listed as "at risk" of extinction by the Rare Breeds Trust of Australia.

(ABC Hobart: Damien Peck)

Tina the Wessex saddleback pig. Her breed is listed as "at risk" of extinction by the Rare Breeds Trust of Australia.

Dr Gressier said the Rare Breeds Trust of Australia had a comprehensive list of animals lost, critical, endangered, or vulnerable.

It lists six breeds of sheep as lost, four of pigs, and 10 of cattle.

"In Australia we used to have a really diverse dairy industry with a number of breeds producing milk," she said.

"Now it's about 70 per cent Holstein which produce milk in the kinds of volumes of scale required to meet market demands.

"Chickens are also faring really poorly, particularly meat birds.

"There are very few farmers who are managing to commercially produce meat chickens that aren't the Ross or the Cobb breed."

Dr Gressier is about to lead a UWA-based study of rare breeds being farmed across Australia to understand why farmers stick with rare breed farming and how their work can be better supported.

See more here:
Extinction of farm animals threatens food security and genetic diversity - ABC News

Updated Genetic Screening Guidelines Published by National Comprehensive Cancer Network Feature Emerging Evidence on Personalized Medicine – Daily…

PLYMOUTH MEETING, Pa., Dec. 4, 2019 /CNW/ --The National Comprehensive Cancer Network (NCCN) today announced publication of the newest genetic risk assessment recommendations for breast, ovarian and pancreatic cancers. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 1.2020 contains several updatesincluding new and expanded sections on risk assessment and management related to three major cancer typeswhile also maintaining a more conservative approach toward testing practices where the evidence is still lacking. In the rapidly-moving field of cancer care and genetics, NCCN Guidelines synthesize the latest evidence and expert consensus to ensure recommendations are firmly supported by quality research, in order to establish best management paradigms that improve outcomes for people with cancer.

"These guidelines are as inclusive as possible, wherever there's strong, unbiased evidence to back up our recommendations," said Mary B. Daly, MD, PhD, FACP, Fox Chase Cancer Center, Chair of the NCCN Guidelines Panel for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. "The guidelines include genes that have been found to increase cancer-susceptibility. These NCCN Guidelines still have a strong focus on BRCA1 and 2 mutations, but also now include other high and moderate penetrance genes associated with breast, ovarian, and pancreatic cancer. We continuously review any new data on genes that might increase a person's risk of getting cancer or impact the effectiveness of their treatment."

The updated guidelines are concentrated around simplified criteria to clarify the genetic testing process. For example, in a newly-added guide for individuals of Ashkenazi Jewish ancestry who have not been diagnosed with cancer, genetic testing may be offered for the three Ashkenazi Jewish founder mutations in the context of a long-term research study, regardless of family history. These individuals should be encouraged to consult with a cancer genetics professional.

The NCCN Guidelines for Genetic/Familial High-Risk Assessment are organized by both disease and syndrome type, and also now include streamlined information on appropriate subsequent steps for persons who meet criteria for genetic testing. The panel acknowledges that genetic mutations can impact the approach to cancer treatment, and the guidelines now state that testing may be clinically indicated if it will aid in systemic therapy decision-making.

"Genetic testing is becoming increasingly utilized in oncology because of its potential to impact surgical decisions and chemotherapy," explained Robert Pilarski, MS, LGC; MSW, Licensed Genetic Counselor, Professor, Clinical Internal Medicine, The Ohio State University Comprehensive Cancer Center, Vice-Chair of the NCCN Guidelines Panel for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. "At the same time, the complexity of this testing is increasing, with a growing number of genes and tests available,a limited understanding of the management implications of some of the newer genes, and even uncertainty over the implications of mutations in well-established genes in some situations (for example in a condition known as 'mosaicism,' in which the mutation is not present in all of the cells of the body). Because of this, the NCCN Guidelines continue to highlight the critical importance of genetic counseling for patients prior to undergoing genetic testing to ensure that patients are fully informed of the test implications."

Pilarski also offered an important word of caution about the potential risks from direct-to-consumer genetic testing: "More and more patients are presenting to clinic having already had themselves tested through direct-to-consumer labs. Providers need to be aware that the tests offered by many of these labs are not equivalent to traditional genetic testing, and the results may need to be confirmed in another laboratory before being used for clinical care."

The guidelines recommend all pancreatic cancer patients get genetic testing, and the recent update now includes more information about which genes are associated with pancreatic cancer recommendations. Genetic testing in pancreatic cancer can help determine which treatments would be most effective (e.g. PARP inhibitors) and if family members would benefit from screening and preventive action.

"There's been an explosion of recent data showing that roughly 4-10% of individuals with pancreatic cancer harbor inherited genetic mutations, including BRCA1, BRCA2, ATM, the Lynch syndrome genes, and others," said Matthew B. Yurgelun, MD, Dana-Farber/Brigham and Women's Cancer Center, Member of the NCCN Guidelines Panel for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. "Such data have, surprisingly, shown that classic 'high-risk' features of inherited cancer risk (e.g. young age at diagnosis, strong family histories of cancer) are often absent in individuals with pancreatic cancer who carry these mutations. Based off of these data, there is now a compelling reason for all individuals with pancreatic cancer to be offered genetic counseling and germline testing for such variantsparticularly given the possibility that their at-risk family members could greatly benefit from known, effective cancer risk-reducing interventions (e.g. surgical removal of the ovaries for female BRCA1/2 mutation carriers). Emerging data have also begun to suggest possible benefits to pancreatic cancer screening in select high-risk individuals who harbor such mutations. These new guidelines address many of the important nuances and limitations of this exciting and rapidly evolving body of literature."

The NCCN Guidelines for Genetic/Familial High-Risk Assessment are created and maintained by an interdisciplinary panel of experts from the alliance of 28 leading cancer centers that comprise NCCN. NCCN panels also include patients and advocates to make sure treatment recommendations meet the needs of people with cancer and their caregivers.

"Participating on the NCCN panel allows FORCE to share the real-world experiences of patients making complex, and often agonizing medical decisions about hereditary cancer treatment and risk management," said Sue Friedman, DVM, Executive Director, Facing Our Risk of Cancer Empowered (FORCE), Member of the NCCN Guidelines Panel for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. "As an advocacy organization for people and families affected by hereditary cancer, we see the importance of having standardized guidelines. These guidelines are a critical piece of informed decision-making; we frequently direct our community to NCCN for up-to-date, clear, and credible information developed by experts in the field."

NCCN Guidelines are the recognized standard for clinical policy in cancer care and are the most thorough and frequently updated clinical practice guidelines available in any area of medicine. The intent of the NCCN Guidelines is to assist in the decision-making process of individuals involved in cancer careincluding physicians, nurses, pharmacists, payers, patients and their familieswith the ultimate goal of improving patient care and outcomes. In addition to covering at least 97 percent of cancers affecting patients in the United States, there are also NCCN Guidelines for detection, prevention, risk-reduction (including smoking cessation), supportive care (including the management of pain, distress, and fatigue), and guidelines for specific populations (including children and young adults).

NCCN Guidelines are available free-of-charge for non-commercial use at NCCN.org, or via the Virtual Library of NCCN Guidelines App.

About the National Comprehensive Cancer NetworkThe National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world.

The NCCN Member Institutions are: Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA; Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope National Medical Center, Duarte, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; O'Neal Comprehensive Cancer Center at UAB, Birmingham, AL; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Rogel Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news. Follow NCCN on Twitter @NCCN, Facebook @NCCNorg, and Instagram @NCCNorg.

Media Contact: Rachel Darwin267-622-6624darwin@nccn.org

See the article here:
Updated Genetic Screening Guidelines Published by National Comprehensive Cancer Network Feature Emerging Evidence on Personalized Medicine - Daily...

Seattle Genetics Announces Updated Data of ADCETRIS (Brentuximab Vedotin) in Combination with OPDIVO (Nivolumab) in Frontline and Relapsed or…

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced updated and long-term follow-up analyses from two clinical trials evaluating ADCETRIS (brentuximab vedotin) and OPDIVO (nivolumab) in frontline Hodgkin lymphoma (HL) patients aged 60 years and older and in relapsed or refractory classical HL. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL. ADCETRIS and OPDIVO are not approved in combination for the treatment of HL. Results were presented today at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 7-10 in Orlando, Fla.

We continue to evaluate ADCETRIS in combination with novel therapies, such as checkpoint inhibitors, with the goal of identifying new options for CD30-expressing lymphomas where there is high unmet need, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. These data presentations at ASH reinforce our strong commitment to the ADCETRIS clinical development program, potentially moving into new patient populations and novel combination treatment strategies.

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged 60 Years (Abstract #237, oral presentation at 2:30 p.m. ET on Saturday, December 7, 2019)Data were presented from an updated analysis from the phase 2 clinical trial evaluating ADCETRIS in combination with OPDIVO as frontline therapy for HL patients aged 60 years and older. Data were reported from 21 patients, and the median age was 72 years. The majority of patients (76 percent) had stage III/IV disease at the time of diagnosis. These results will be highlighted in an oral presentation by Christopher A. Yasenchak, M.D., Willamette Valley Cancer Institute and Research Center/US Oncology Research, Ore., and include:

Two-Year Follow-up Results from the Phase 1-2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (Abstract #238, oral presentation at 2:45 p.m. ET on Saturday, December 7, 2019)Data were reported from 93 patients with relapsed or refractory classical HL after failure of frontline therapy who received the combination regimen of ADCETRIS plus OPDIVO. After completion of the fourth cycle of treatment, patients were eligible to undergo an autologous stem cell transplant (ASCT). The median age of patients was 34 years. These results will be highlighted in an oral presentation by Alison J. Moskowitz, M.D., Memorial Sloan Kettering Cancer Center, NY, and include:

About Classical Hodgkin LymphomaLymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Classical Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. The Reed-Sternberg cell expresses CD30.

According to the American Cancer Society, approximately 8,110 cases of Hodgkin lymphoma will be diagnosed in the United States during 2019 and 1,000 will die from the disease. Approximately half of all newly diagnosed Hodgkin lymphoma patients have Stage III/IV disease. According to the Lymphoma Coalition, over 62,000 people worldwide are diagnosed with Hodgkin lymphoma each year and approximately 25,000 people die each year from this cancer.

About ADCETRISADCETRIS is being evaluated broadly in more than 70 clinical trials in CD30-expressing lymphomas. These include three completed phase 3 trials: ECHELON-2 trial in frontline peripheral T-cell lymphomas, ECHELON-1 in previously untreated Hodgkin lymphoma, and ALCANZA in cutaneous T-cell lymphoma.

ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

ADCETRIS injection for intravenous infusion has received FDA approval for six indications in adult patients with: (1) previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone, (2) previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine, (3) cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation, (4) cHL after failure of auto-HSCT or failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates, (5) sALCL after failure of at least one prior multi-agent chemotherapy regimen, and (6) primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.

Health Canada granted ADCETRIS approval with conditions in 2013 for patients with (1) HL after failure of autologous stem cell transplant (ASCT) or after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates and (2) sALCL after failure of at least one multi-agent chemotherapy regimen. Non-conditional approval was granted for (3) post-ASCT consolidation treatment of patients with HL at increased risk of relapse or progression in 2017, (4) adult patients with pcALCL or CD30-expressing MF who have received prior systemic therapy in 2018, (5) for previously untreated patients with Stage IV HL in combination with doxorubicin, vinblastine, and dacarbazine in 2019, and (6) for previously untreated adult patients with sALCL, peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumors express CD30, in combination with cyclophosphamide, doxorubicin, prednisone in 2019.

ADCETRIS received conditional marketing authorization from the European Commission in October 2012. The approved indications in Europe are: (1) for the treatment of adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma following ASCT, or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, (2) for the treatment of adult patients with relapsed or refractory sALCL, (3) for the treatment of adult patients with CD30-positive Hodgkin lymphoma at increased risk of relapse or progression following ASCT, (4) for the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy and (5) for the treatment of adult patients with previously untreated CD30-positive Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine and dacarbazine).

ADCETRIS has received marketing authorization by regulatory authorities in 73 countries for relapsed or refractory Hodgkin lymphoma and sALCL. See select important safety information, including Boxed Warning, below.

Seattle Genetics and Takeda are jointly developing ADCETRIS. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has rights to commercialize ADCETRIS in the rest of the world. Seattle Genetics and Takeda are funding joint development costs for ADCETRIS on a 50:50 basis, except in Japan where Takeda is solely responsible for development costs.

About Seattle GeneticsSeattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) utilizes the companys industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has a late-stage pipeline including enfortumab vedotin for metastatic urothelial cancer, currently being reviewed for approval by the FDA, and tisotumab vedotin in clinical trials for metastatic cervical cancer, which utilize our proprietary ADC technology. In addition, tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer and in clinical development for metastatic colorectal cancer. We are also leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors. The company is headquartered in Bothell, Washington, and has a European office in Switzerland. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

ADCETRIS (brentuximab vedotin) U.S. Important Safety Information

BOXED WARNINGPROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): JC virus infection resulting in PML and death can occur in ADCETRIS-treated patients.

ContraindicationADCETRIS concomitant with bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation).

Warnings and Precautions

Most Common (20% in any study) Adverse Reactions: Peripheral neuropathy, fatigue, nausea, diarrhea, neutropenia, upper respiratory tract infection, pyrexia, constipation, vomiting, alopecia, decreased weight, abdominal pain, anemia, stomatitis, lymphopenia and mucositis.

Drug InteractionsConcomitant use of strong CYP3A4 inhibitors or inducers has the potential to affect the exposure to monomethyl auristatin E (MMAE).

Use in Specific PopulationsModerate or severe hepatic impairment or severe renal impairment: MMAE exposure and adverse reactions are increased. Avoid use.

Advise males with female sexual partners of reproductive potential to use effective contraception during ADCETRIS treatment and for at least 6 months after the final dose of ADCETRIS.

Advise patients to report pregnancy immediately and avoid breastfeeding while receiving ADCETRIS.

Please see the full Prescribing Information, including BOXED WARNING, for ADCETRIS here.

Forward Looking StatementsCertain of the statements made in this press release are forward looking, such as those, among others, relating to the potential uses and benefits of ADCETRIS (brentuximab vedotin) in combination with OPDIVO (nivolumab) in frontline Hodgkin lymphoma (HL) patients age 60 years or older and in relapsed or refractory classical HL under staggered and concurrent dosing schedules, the therapeutic potential of ADCETRIS in these indications and the companys clinical development plans. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include potential lack of efficacy or risk of adverse events associated with the use of ADCETRIS in certain clinical settings and the difficulty and uncertainty of pharmaceutical product development. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Opdivo is a registered trademark of Bristol-Myers Squibb Company.

Go here to see the original:
Seattle Genetics Announces Updated Data of ADCETRIS (Brentuximab Vedotin) in Combination with OPDIVO (Nivolumab) in Frontline and Relapsed or...

Human Genetics Market: Competitive Landscape & Growth Opportunities | QIAGEN, Agilent Technologies, Thermo Fisher Scientific – Kentucky Reports

Global Human Genetics Market Size, Status and Forecast 2019-2025is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The influencing Factors of the report is growth of this market include authorized regulations with respect to the usage of the information, availability of highly reliable products in the market, and increase in operational efficiency of.The study provides information on market trends and development, drivers, capacities, technologies, and on thechanging dynamics of Global Human Genetics Market. As per study key players of this market are QIAGEN, Agilent Technologies, Thermo Fisher Scientific, Illumina, Promega, LabCorp & GE.

Click To get SAMPLE PDF (Including Full TOC, Table & Figures)

#Summary:In 2018, the global Human Genetics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Human Genetics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Human Genetics development in North America, Europe and Asia-Pacific.

Global Human GeneticsMarket and Competitive AnalysisKnow your current market situation! Not only an important element for new products but also for current products given the ever-changing market dynamics. The study allows marketers to stay in touch with current consumer trends and segments where they can face rapid market share drop. Discover who you really compete against in the marketplace, with Market Share Analysis know market position, % market Share and Segmented Revenue of

Some Players from Research Coverage:QIAGEN, Agilent Technologies, Thermo Fisher Scientific, Illumina, Promega, LabCorp & GE

Additionally, Chapters on Historical & Current Global Human Genetics Market Development Scenario, Market Entropy to Race Aggressiveness and Patent Analysis* is covered along with Competitors Swot Analysis, Product Specifications and Peer Group Analysis with important financial metrics like Gross Margin, Total Revenue, Segment Revenue, Employee Size, Net Profit, Total Assets etc.

Segmentation and TargetingEssential demographic, geographic, psycho-graphic and behavioral information about businesses segments in the Human Genetics market is targeted to aid in determining the features company should encompass in order to fit into the businesses requirements.

Human Genetics Product Types In-Depth:, Cytogenetics, Prenatal Genetics, Molecular Genetics & Symptom GeneticsHuman Genetics Major Applications/End users:Research Center, Hospital & Forensic LaboratoriesHuman Genetics Major Geographical First Level Segmentation:North America, Europe & Asia-Pacific***

*** For global version, list of below countries by region can be added as part of customization at minimum cost.North America (United States, Canada & Mexico)Asia-Pacific (Japan, China, India, Australia etc)Europe (Germany, UK, France etc)Central & South America (Brazil, Argentina etc)Middle East & Africa (United Arab Emirates, Saudi Arabia, South Africa etc)

Buy Full Copy Global Human Genetics Report 2019 @https://www.htfmarketreport.com/buy-now?format=1&report=2175025

Human Genetics Product/Service DevelopmentKnowing how the product/services fits the needs of clients and what changes would require to make the product more attractive is need of an hour. Useful approaches on focus group by utilizing User Testing and User Experience Research. Demand side analysis always helps to correlate consumer preferences with innovation.Human Genetics Product Types In-Depth:, Cytogenetics, Prenatal Genetics, Molecular Genetics & Symptom Genetics**

** Further Smaller or Narrow Segments by Type Can be Included on Clients Request based on FeasibilityEnquire for customization in Report @https://www.htfmarketreport.com/enquiry-before-buy/2175025-global-human-genetics-market

Marketing Communication and Sales ChannelUnderstanding marketing effectiveness on a continual basis help determine the potential of advertising and marketing communications and allow to use best practices to utilize untapped audience. In order to make marketers make effective strategies and identify why target market is not giving attention we ensure Study is Segmented with appropriate marketing & sales channels to identify potential market size by Revenue and Volume* (if Applicable).

Extracts from TOC1 Study CoverageIndustry Definition2. Executive SummaryGlobal Human Genetics Market Size (2014-2025) by Revenue, Production*, Growth rateAnalysis of Competitive Landscape Insights on Market Development Scenario3. Market Size by Manufacturers [Market Share, Global Rank etc]4. Global Human Genetics Production, Consumption by Regions (2014-2025)5. Market Size by TypeGlobal Human Genetics Revenue by TypeGlobal Human Genetics Volume by TypeGlobal Human Genetics Price by Type6. Market Size by Application (2014-2025)Global Human Genetics Breakdown Data by Revenue, Volume7. Manufacturers Profiles8. Value Chain and Sales Channels Analysis

Browse for Full Report at @:https://www.htfmarketreport.com/reports/2175025-global-human-genetics-market

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]Connect with us atLinkedIn|Facebook|Twitter

Continue reading here:
Human Genetics Market: Competitive Landscape & Growth Opportunities | QIAGEN, Agilent Technologies, Thermo Fisher Scientific - Kentucky Reports